Ravi Shekhar Mitra
CFO, Gland Pharma
Notable Quotes
Price overall is stable if you look at from the previous quarter to current. The relaunches what we have done, out of 14 products in the U.S. what we launched, 4 are entirely new and about 10 are relaunches.
We are currently analyzing that data. As of now, in the near term, it is not, but we'll see how the efficiency increases.